MRKR VS XGN Stock Comparison

PerformanceTechnicalsEarningsProfitVolatilitySentiment
PerformanceTechnicalsEarningsProfitVolatilitySentiment

Performance

MRKR
10/100

MRKR returned -20.79% in the last 12 months. Based on SPY's performance of -13.80%, its performance is below average giving it a score of 10 of 100.

XGN
10/100

XGN returned -48.68% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

MRKR
21/100

MRKR receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

XGN
14/100

XGN receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

Earnings

MRKR
10/100

MRKR has missed earnings 6 times in the last 20 quarters.

XGN
33/100

XGN has missed earnings 4 times in the last 20 quarters.

Profit

MRKR
10/100

Out of the last 20 quarters, MRKR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

XGN
10/100

Out of the last 20 quarters, XGN has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

MRKR
58/100

MRKR has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

XGN
52/100

XGN has had a higher than average amount of volatility over the last 12 months giving it a score of 51 of 100.

Sentiment

MRKR

"Sentiment" not found for MRKR

XGN
68/100

XGN had a bullish sentiment score of 68.07% across Twitter and StockTwits over the last 12 months. It had an average of 2.75 posts, 0.12 comments, and 0.25 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Marker Therapeutics, Inc. Common Stock Summary

Nasdaq / MRKR
Healthcare
Biotechnology
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

Exagen Inc. Common Stock Summary

Nasdaq / XGN
Healthcare
Medical - Diagnostics & Research
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.